Laurus Labs gets DRDO licence to make anti-COVID drug 2DG
The Hindu
Drugs Controller General of India (DCGI) had on May 1 accorded emergency approval for use of 2DG on COVID-19 patients.
Drugmaker Laurus Labs has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market 2-Deoxy-D-Glucose (2DG), an oral drug indicated as an adjunct therapy for hospitalised COVID-19 patients. Announcing this, the company said it has already applied for emergency use authorisation for the product with the Central Drugs Standard Control Organization. The Drugs Controller General of India (DCGI) had on May 1 accorded emergency approval for use of 2DG on COVID-19 patients. Laurus Labs is among a clutch of companies that have been issued licence to manufacture and market 2-DG, sources said. DRDO had last month invited expression of interest, from pharma companies, offering transfer of technology of the process for manufacturing 2-DG.More Related News

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












